Document Detail


Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation.
MedLine Citation:
PMID:  23273695     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Seven patients with venous thrombosis and contraindications to traditional thrombolytic therapy, consisting of recent intracranial surgery, recent pineal or retroperitoneal hemorrhage, active genitourinary or gastrointestinal bleeding, epidural procedures, and impending surgery, were successfully treated with a modified thrombolytic regimen. To improve safety, prolonged continuous infusions of tissue plasminogen activator (tPA) was eliminated in favor of once-daily low-dose intraclot injections of tPA to minimize the amount and duration of tPA in the systemic circulation, and low-therapeutic or regional anticoagulation was used to reduce anticoagulant risks. These modifications may allow thrombolytic treatment for selected patients with severe venous thrombosis who are deemed to be at high risk.
Authors:
Richard Chang; John A Butman; Russell R Lonser; Richard M Sherry; Prakash K Pandalai; McDonald K Horne; Jay N Lozier
Related Documents :
22953685 - Individualized quantified tricuspid valve annuloplasty for treating ebstein anomaly.
24612465 - Bivalirudin: treatment effect vs. side effect.
24047455 - Effects of bracing in adolescents with idiopathic scoliosis.
24026305 - Management of benign tracheal strictures caused by tracheostomy.
15318045 - Management of sternal wounds with bilateral pectoralis major myocutaneous advancement f...
22953685 - Individualized quantified tricuspid valve annuloplasty for treating ebstein anomaly.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Journal of vascular and interventional radiology : JVIR     Volume:  24     ISSN:  1535-7732     ISO Abbreviation:  J Vasc Interv Radiol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-31     Completed Date:  2013-07-09     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9203369     Medline TA:  J Vasc Interv Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  27-34.e1     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anticoagulants / administration & dosage*
Dose-Response Relationship, Drug
Drug Therapy, Combination / methods
Female
Fibrinolytic Agents / administration & dosage
Humans
Male
Middle Aged
Recombinant Proteins / administration & dosage
Tissue Plasminogen Activator / administration & dosage*,  genetics
Treatment Outcome
Venous Thrombosis / drug therapy*
Grant Support
ID/Acronym/Agency:
Z99 CL999999/CL/CLC NIH HHS; ZIA CL010343-06/CL/CLC NIH HHS; ZIA CL010343-07/CL/CLC NIH HHS; ZIA CL010343-08/CL/CLC NIH HHS; ZIA CL010343-09/CL/CLC NIH HHS
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer a...
Next Document:  Preoperative Inferior Mesenteric Artery Embolization before Endovascular Aneurysm Repair: Decreased ...